BELIMUMAB: ADVANCES IN DRUG THERAPY FOR SYSTEMIC LUPUS ERYTHEMATOSUS

1. <div><p>Клюквина Н.Г. Системная красная волчанка. В кн.: Ревматология: Национальное руководство. Под ред. Е.Л. Насонова и В.А. Насоновой. М.: ГЭОТАР-Медиа, 2008; 419—46.</p><p>Rahman A., Isenberg D.A. Systemic lupus erythematosus. N Engl J Med 2008; 358: 929-39.</p><p>Helmick C.G., Felson D.T., Lawrence R.C. et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthr Rheum 2008; 58: 15-25</p><p>Pons-Estel G.J., Alarcon G.S., Scofield L. et al. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthr Rheum 2010; 39: 257-68.</p><p>Manson J.J., Ma A., Rogers P. et al. Relationship between antidsDNA, anti-nucleosome and anti-alpha-actin antibodies and markers of renal disease in patients with lupus nephritis: A prospective longitudinal study. Arthr Res Ther 2009; 11: R154.</p><p>Системная красная волчанка. В кн.: Ревматология: Клинические рекомендации. Под ред. Е.Л. Насонова. М.: ГЭОТАР-Медиа, 2010; 429—81.</p><p>Wallace D.J. Advances in drug therapy for systemic lupus erythematosus. BMC Med 2010; 8: 77.</p><p>Соловьев С.К., Торгашина А.Г., Насонов Е.Л. В кн.: Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. Под ред. Е.Л. Насонова. М.: ИМА-ПРЕСС, 2012; 119—52.</p><p>Merrill J.T., Neuwelt C.M., Wallace D.J. et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthr Rheum 2010; 62: 222—33.</p><p>Rovin B.R., Furie R., Latinis K. et al. Efficacy and safety of Rituximab in patients with active prolipherative lupus nephritis: the LUpis Nephritis Assessment with Rituximab (LUNAR) study. Arthr Rheum 2011, June 10 [Epub. ahead of print].</p><p>Bruce I.N. Re-evalution of biologic therapy in systemic lupus erythematosus. Curr Opin Rheumatol 2010; 22(3): 273—7.</p><p>FDA approves Benlysta to treat lupus. [Last accessed on 2011 Mar 28]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm246489.htm</p><p>European Medicines Agency. Benlysta: belimumab. 9cited August 8, 2011). Available from: www.ema.ruropa.eu/ema/index/jsp?curl=pages/medicines/human/medicines.002015/human_med_001466.jsp&amp;mid=WC0bac058001d124</p><p>Merrill J.T. Ending the 50-year drought of FDA drug approval for SLE. Bull NYU Hosp Joint Dis 2011; 69: 238-42.</p><p>Stohl W. The discovery and development of belimumab: the anti-BlyS-lupus connection. Nature Biotechnol 2012; 30: 69-77.</p><p>Littman B.H. Translation strategies to implement personalized medicine: rheumatoid arthritis examples. Personal Med 2009; 6: 429-37.</p><p>Lied G.A., Berstad A. Functional and clinical aspects of the B-cell-activation factor (BAFF): a narrative review. Scand J Immunol 2011; 73: 1-7</p><p>Moore P.A., Belvedere O., Orr A. et al. BLyS: Member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999; 285: 260-3.</p><p>Schneider P., MacKay F., Steiner V. et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999; 189: 1747-56.</p><p>Treml J.F., Hao Y., Stadanlick J.E. et al. The BLyS family: Toward a molecular understanding of B cell homeostasis. Cell Biochem Biophys 2009; 53: 1-16.</p><p>Cancro M.P. The BLyS/BAFF family of ligands and receptors: Key targets in the therapy and understanding of autoimmunity. Ann Rheum Dis 2006; 65: 34-6.</p><p>Mackay F., Woodcock S.A., Lawton P. et al. Mice Transgenic for BAFF Develop Lymphocytic Disorders along with Autoimmune Manifestations. J Exp Med 1999; 190: 1697-710.</p><p>Gross J.A., Johnston J., Murdi S. et al. TACI and BCMA are receptors for TNF homologue implicated in B-cell autoimmune disease. Nature 2000; 404: 995-9.</p><p>Stohl W., Metyas S., Tan S.M. et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: Longitudinal observations. Arthr Rheum 2003; 48: 3475-86.</p><p>Petri M., Stohl W., Chatham W. et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthr Rheum 2008; 58: 2453-9.</p><p>Sanz I. Targeting B cell in SLE: good news at last. Nat Rev Rheum, 2011 [Epub. ahead of print].</p><p>Halpern W.G., Lappin P., Zanardi T. et al. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: Pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicol Sci 2006; 91: 586-99.</p><p>Baker K.P., Edwards B.M., Main S.H. et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthr Rheum 2003; 48: 3253-65.</p><p>Label approved on 03/10/2011 (PDF) for BENLYSTA, BLA no. 125370 [Last accessed 2011 Mar 28]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/12537 0s0000lbl.pdf</p><p>Furie R., Stohl W., Ginzler E.M. et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthr Res Ther 2008; 10: R109.</p><p>Wallace D.J., Stohl W., Ginzler E.M. et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of beli-mumab in patients with active systemic lupus erythematosus. Arthr Rheum 2009; 61; 1168-78.</p><p>Furie R.A., Petri M.A., Wallace D.J. et al. Novel evidence-based systemic lupus erythematosus responder index. Arthr Rheum 2009; 61: 1143-51.</p><p>Navarra S.V., Guzman R.M., Gallacher A.E. et al. BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 721-31.</p><p>Furie R., Petri M., Zamani E. et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthr Rheum 2011; 63: 3918-30.</p><p>Manzi S., Sanchez-Guerrero J., Merrill J.T. et al. Effects of beli-mumab, a B lymphocyte stimulator-specigic inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 2012; May 1 [Epub. ahead of print].</p><p>Stohl W., Hiepe F., Latinis K.M. et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in the patients with systemic lupus erythematosus. Arthr Rheum 2012; 64: 2328-37.</p><p>Van Vollenhoven R.F., Petri M.A., Cervera R. et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 2012; 5 April [Epub. ahead of print].</p><p>Jacobi A.M., Odendahl M., Reiter K. et al. Correlation between circulating CD29high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthr Rheum 2003; 48: 1332-42.</p><p>Petri M., Singh S., Tesfasyone H. et al. Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective study. J Rheum 2009; 36: 2476-80.</p><p>Tseng C.E., Buyon J.P., Kim M. et al. The effect of moderate dose corticosteroids in preventing of severe flares in patients with serologically active, but clinically stable systemic lupus erythematosus: finding of a prospective, randomized, double-blind, placebo-controlled trial. Arthr Rheum 2006; 54: 3623-32.</p><p>Merril J.T., Ginzler E.M., Wallace D.J. et al. Long-term safety profile of belimumab plus standart therapy in patients with systemic lupus erythematosus. Arthr Rheum 2012; May 24 [Epub. ahead of print].</p><p>Chatham W., Wallace D.J., Stohl W. et al. Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines. In patients with systemic lupus erythematosus in the BLISS-76 trial. J Rheum 2012; 39: 1632-40.</p></div><br />